Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

2.

Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.

Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, Yao Y, He F, Lu CX, Guagnano V, Metz T, Finan PM, Hofmann F, Sellers WR, Porter JA, Myer VE, Graus-Porta D, Wilson CJ, Buckler A, Tiedt R.

Cancer Discov. 2012 Oct;2(10):948-59. doi: 10.1158/2159-8290.CD-12-0237. Epub 2012 Aug 8.

3.

Caveolae: biochemical analysis.

Chatenay-Rivauday C, Cakar ZP, Jenö P, Kuzmenko ES, Fiedler K.

Mol Biol Rep. 2004 Jun;31(2):67-84.

PMID:
15293782
4.
5.

TNF-alpha release by monocytic THP-1 cells through cross-linking of the extended V-region of the oral streptococcal protein I/II.

Chatenay-Rivauday C, Yamodo I, Sciotti MA, Troffer-Charlier N, Klein JP, Ogier JA.

J Leukoc Biol. 2000 Jan;67(1):81-9.

PMID:
10648001
6.
7.

The N-terminal half part of the oral streptococcal antigen I/IIf contains two distinct functional domains.

Sciotti MA, Chatenay-Rivauday C, Yamodo I, Ogier J.

Adv Exp Med Biol. 1997;418:699-701. No abstract available.

PMID:
9331747

Supplemental Content

Loading ...
Support Center